English

ImmunoPrecise Antibodies Ltd.

EDGAR

HYFT Report (type unavailable) · filed 2026-10-06

Annual consolidated revenue for 2026: about CAD 15.56M, using the latest reported figures. The previous period, 2025, was about CAD 10.63M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

3.83 million CAD

2027 Q1 · CAD

Exact inputs and evidence

Revenue: 3834000 CAD Source

Free cash flow margin

-107.46%

2027 Q1 · %

Exact inputs and evidence

Revenue: 3834000 CAD Source
Operating Cash Flow: -4042000 CAD Source
Capital Expenditure: 78000 CAD Source

Operating cash flow

-4.04 million CAD

2027 Q1 · CAD

Exact inputs and evidence

Operating Cash Flow: -4042000 CAD Source

Free cash flow

-4.12 million CAD

2027 Q1 · CAD

Exact inputs and evidence

Operating Cash Flow: -4042000 CAD Source
Capital Expenditure: 78000 CAD Source

Cash and cash equivalents: 7.75 million CAD 2026-07-31 Source
Exact value

7751000 CAD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

16.2 million CAD

2025-08-01 – 2026-07-31

Exact inputs and evidence

Revenue: 4124000 CAD · 2025-08-01 – 2025-10-31 Source
Revenue: 4158000 CAD · 2025-11-01 – 2026-01-31 Source
Revenue: 15558000 CAD · 2025-05-01 – 2026-04-30 Source
Revenue: 11443000 CAD · 2025-05-01 – 2026-01-31 Source
Revenue: 3834000 CAD · 2026-05-01 – 2026-07-31 Source

Operating cash flow

-12.3 million CAD

2025-08-01 – 2026-07-31

Exact inputs and evidence

Operating cash flow: -7083000 CAD · 2025-05-01 – 2025-10-31 Source
Operating cash flow: -4213000 CAD · 2025-05-01 – 2025-07-31 Source
Operating cash flow: -10055000 CAD · 2025-05-01 – 2026-01-31 Source
Operating cash flow: -7083000 CAD · 2025-05-01 – 2025-10-31 Source
Operating cash flow: -12463000 CAD · 2025-05-01 – 2026-04-30 Source
Operating cash flow: -10055000 CAD · 2025-05-01 – 2026-01-31 Source
Operating cash flow: -4042000 CAD · 2026-05-01 – 2026-07-31 Source

Capital expenditure

194 thousand CAD

2025-08-01 – 2026-07-31

Exact inputs and evidence

Capital expenditure: 356000 CAD · 2025-05-01 – 2025-10-31 Source
Capital expenditure: 282000 CAD · 2025-05-01 – 2025-07-31 Source
Capital expenditure: 387000 CAD · 2025-05-01 – 2026-01-31 Source
Capital expenditure: 356000 CAD · 2025-05-01 – 2025-10-31 Source
Capital expenditure: 398000 CAD · 2025-05-01 – 2026-04-30 Source
Capital expenditure: 387000 CAD · 2025-05-01 – 2026-01-31 Source
Capital expenditure: 78000 CAD · 2026-05-01 – 2026-07-31 Source

Free cash flow

-12.5 million CAD

2025-08-01 – 2026-07-31

Exact inputs and evidence

Operating cash flow: -7083000 CAD · 2025-05-01 – 2025-10-31 Source
Operating cash flow: -4213000 CAD · 2025-05-01 – 2025-07-31 Source
Operating cash flow: -10055000 CAD · 2025-05-01 – 2026-01-31 Source
Operating cash flow: -7083000 CAD · 2025-05-01 – 2025-10-31 Source
Operating cash flow: -12463000 CAD · 2025-05-01 – 2026-04-30 Source
Operating cash flow: -10055000 CAD · 2025-05-01 – 2026-01-31 Source
Operating cash flow: -4042000 CAD · 2026-05-01 – 2026-07-31 Source
Capital expenditure: 356000 CAD · 2025-05-01 – 2025-10-31 Source
Capital expenditure: 282000 CAD · 2025-05-01 – 2025-07-31 Source
Capital expenditure: 387000 CAD · 2025-05-01 – 2026-01-31 Source
Capital expenditure: 356000 CAD · 2025-05-01 – 2025-10-31 Source
Capital expenditure: 398000 CAD · 2025-05-01 – 2026-04-30 Source
Capital expenditure: 387000 CAD · 2025-05-01 – 2026-01-31 Source
Capital expenditure: 78000 CAD · 2026-05-01 – 2026-07-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-06.

Financial data available through: 2026-04-30.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2026-04-30
operating income: No compatible figures in this window
net income: No compatible figures in this window
Operating cash flow: 7 of 11 periods available· newest 2026-04-30
Capital expenditure: 7 of 11 periods available· newest 2026-04-30
Total assets: 7 of 11 periods available· newest 2026-04-30
Total liabilities: 7 of 11 periods available· newest 2026-04-30
Current assets: 7 of 11 periods available· newest 2026-04-30
Current liabilities: 7 of 11 periods available· newest 2026-04-30
Cash and cash equivalents: 7 of 11 periods available· newest 2026-04-30
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+46.4%

Prior period

CAD 10.63 million

2024-05-01 – 2025-04-30
Current period

CAD 15.56 million

2025-05-01 – 2026-04-30

Exact inputs and evidence

15558000 − 10626000 = 4932000 CAD

10626000 CAD · 2024-05-01 – 2025-04-30
Inspect prior input Prior source
15558000 CAD · 2025-05-01 – 2026-04-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ImmunoPrecise Antibodies Ltd. · 2026-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Year-over-year change in Revenue: 4932000 CAD Concept: fundies:Revenue Period: 2025-05-01 to 2026-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 15558000 CAD (2025-05-01 to 2026-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#5139137 Filing: 000119312526312694 Input fundies:Revenue: 10626000 CAD (2024-05-01 to 2025-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#5140887 Filing: 000119312526312694
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−CAD 6.05 million

Prior period

−CAD 6.41 million

2024-05-01 – 2025-04-30
Current period

−CAD 12.46 million

2025-05-01 – 2026-04-30

Exact inputs and evidence

-12463000 − -6410000 = -6053000 CAD

-6410000 CAD · 2024-05-01 – 2025-04-30
Inspect prior input Prior source
-12463000 CAD · 2025-05-01 – 2026-04-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ImmunoPrecise Antibodies Ltd. · 2026-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Year-over-year change in Operating cash flow: -6053000 CAD Concept: fundies:OperatingCashFlow Period: 2025-05-01 to 2026-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -12463000 CAD (2025-05-01 to 2026-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3095470 Filing: 000119312526312694 Input fundies:OperatingCashFlow: -6410000 CAD (2024-05-01 to 2025-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3097355 Filing: 000119312526312694
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-50.2%

Prior period

CAD 799,000

2024-05-01 – 2025-04-30
Current period

CAD 398,000

2025-05-01 – 2026-04-30

Exact inputs and evidence

398000 − 799000 = -401000 CAD

799000 CAD · 2024-05-01 – 2025-04-30
Inspect prior input Prior source
398000 CAD · 2025-05-01 – 2026-04-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ImmunoPrecise Antibodies Ltd. · 2026-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Year-over-year change in Capital expenditure: -401000 CAD Concept: fundies:CapitalExpenditure Period: 2025-05-01 to 2026-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 398000 CAD (2025-05-01 to 2026-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3106453 Filing: 000119312526312694 Input fundies:CapitalExpenditure: 799000 CAD (2024-05-01 to 2025-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3108220 Filing: 000119312526312694
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Net income.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2026 2025-05-01 – 2026-04-30

Revenue CAD 15.56 million 100% of revenue
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow −CAD 12.46 million −80% of revenue
Capital expenditure CAD 398,000 2.6% of revenue
Free cash flow Derived −CAD 12.86 million −83% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.
2025 Not shown: operating income or net income is not reported.
2026 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2019-05-01 – 2020-04-30	14058000	Unavailable	Unavailable	Unavailable	Unavailable	-1765000 Derived	Source 2019-05-01 – 2020-04-30: 14058000 CAD Inspect Revenue Open source 2019-05-01 – 2020-04-30: -1391000 CAD Inspect Operating Cash Flow Open source 2019-05-01 – 2020-04-30: 374000 CAD Inspect Capital Expenditure Open source
2021 2020-05-01 – 2021-04-30	17912000	Unavailable	Unavailable	Unavailable	Unavailable	-1975000 Derived	Source 2020-05-01 – 2021-04-30: 17912000 CAD Inspect Revenue Open source 2020-05-01 – 2021-04-30: -600000 CAD Inspect Operating Cash Flow Open source 2020-05-01 – 2021-04-30: 1375000 CAD Inspect Capital Expenditure Open source
2022 2021-05-01 – 2022-04-30	19364000	Unavailable	Unavailable	Unavailable	Unavailable	-10987000 Derived	Source 2021-05-01 – 2022-04-30: 19364000 CAD Inspect Revenue Open source 2021-05-01 – 2022-04-30: -9921000 CAD Inspect Operating Cash Flow Open source 2021-05-01 – 2022-04-30: 1066000 CAD Inspect Capital Expenditure Open source
2023 2022-05-01 – 2023-04-30	20665000	Unavailable	Unavailable	Unavailable	Unavailable	-21328000 Derived	Source 2022-05-01 – 2023-04-30: 20665000 CAD Inspect Revenue Open source 2022-05-01 – 2023-04-30: -19833000 CAD Inspect Operating Cash Flow Open source 2022-05-01 – 2023-04-30: 1495000 CAD Inspect Capital Expenditure Open source
2024 2023-05-01 – 2024-04-30	10279000	Unavailable	Unavailable	Unavailable	Unavailable	-4581000 Derived	Source 2023-05-01 – 2024-04-30: 10279000 CAD Inspect Revenue Open source 2023-05-01 – 2024-04-30: -3184000 CAD Inspect Operating Cash Flow Open source 2023-05-01 – 2024-04-30: 1397000 CAD Inspect Capital Expenditure Open source
2025 2024-05-01 – 2025-04-30	10626000	Unavailable	Unavailable	Unavailable	Unavailable	-7209000 Derived	Source 2024-05-01 – 2025-04-30: 10626000 CAD Inspect Revenue Open source 2024-05-01 – 2025-04-30: -6410000 CAD Inspect Operating Cash Flow Open source 2024-05-01 – 2025-04-30: 799000 CAD Inspect Capital Expenditure Open source
2026 2025-05-01 – 2026-04-30	15558000	Unavailable	Unavailable	Unavailable	Unavailable	-12861000 Derived	Source 2025-05-01 – 2026-04-30: 15558000 CAD Inspect Revenue Open source 2025-05-01 – 2026-04-30: -12463000 CAD Inspect Operating Cash Flow Open source 2025-05-01 – 2026-04-30: 398000 CAD Inspect Capital Expenditure Open source

Amounts are exact, in CAD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

CAD 15.6M 2026

Values and sources

Revenue values and source evidence
Period	Series	Value(CAD)	Source evidence
20202020-04-30	Revenue	14058000	Revenue: 14058000 Open source
20212021-04-30	Revenue	17912000	Revenue: 17912000 Open source
20222022-04-30	Revenue	19364000	Revenue: 19364000 Open source
20232023-04-30	Revenue	20665000	Revenue: 20665000 Open source
20242024-04-30	Revenue	10279000	Revenue: 10279000 Open source
20252025-04-30	Revenue	10626000	Revenue: 10626000 Open source
20262026-04-30	Revenue	15558000	Revenue: 15558000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

46.4% 2026

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-04-30	Year over year	No prior comparable period	Revenue: 14058000 Open source
20212021-04-30	Year over year	27.4%	Revenue: 17912000 Open source Revenue: 14058000 Open source
20222022-04-30	Year over year	8.1%	Revenue: 19364000 Open source Revenue: 17912000 Open source
20232023-04-30	Year over year	6.7%	Revenue: 20665000 Open source Revenue: 19364000 Open source
20242024-04-30	Year over year	-50.3%	Revenue: 10279000 Open source Revenue: 20665000 Open source
20252025-04-30	Year over year	3.4%	Revenue: 10626000 Open source Revenue: 10279000 Open source
20262026-04-30	Year over year	46.4%	Revenue: 15558000 Open source Revenue: 10626000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Free cash flow margin -82.7% 2026

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2020-04-30	Operating margin	Not reported	Revenue: 14058000 Open source
2021-04-30	Operating margin	Not reported	Revenue: 17912000 Open source
2022-04-30	Operating margin	Not reported	Revenue: 19364000 Open source
2023-04-30	Operating margin	Not reported	Revenue: 20665000 Open source
2024-04-30	Operating margin	Not reported	Revenue: 10279000 Open source
2025-04-30	Operating margin	Not reported	Revenue: 10626000 Open source
2026-04-30	Operating margin	Not reported	Revenue: 15558000 Open source
2020-04-30	Net margin	Not reported	Revenue: 14058000 Open source
2021-04-30	Net margin	Not reported	Revenue: 17912000 Open source
2022-04-30	Net margin	Not reported	Revenue: 19364000 Open source
2023-04-30	Net margin	Not reported	Revenue: 20665000 Open source
2024-04-30	Net margin	Not reported	Revenue: 10279000 Open source
2025-04-30	Net margin	Not reported	Revenue: 10626000 Open source
2026-04-30	Net margin	Not reported	Revenue: 15558000 Open source
20202020-04-30	Free cash flow margin	-12.6%	Revenue: 14058000 Open source Operating Cash Flow: -1391000 Open source Capital Expenditure: 374000 Open source
20212021-04-30	Free cash flow margin	-11%	Revenue: 17912000 Open source Operating Cash Flow: -600000 Open source Capital Expenditure: 1375000 Open source
20222022-04-30	Free cash flow margin	-56.7%	Revenue: 19364000 Open source Operating Cash Flow: -9921000 Open source Capital Expenditure: 1066000 Open source
20232023-04-30	Free cash flow margin	-103.2%	Revenue: 20665000 Open source Operating Cash Flow: -19833000 Open source Capital Expenditure: 1495000 Open source
20242024-04-30	Free cash flow margin	-44.6%	Revenue: 10279000 Open source Operating Cash Flow: -3184000 Open source Capital Expenditure: 1397000 Open source
20252025-04-30	Free cash flow margin	-67.8%	Revenue: 10626000 Open source Operating Cash Flow: -6410000 Open source Capital Expenditure: 799000 Open source
20262026-04-30	Free cash flow margin	-82.7%	Revenue: 15558000 Open source Operating Cash Flow: -12463000 Open source Capital Expenditure: 398000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

CAD -12.5M 2026

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(CAD)	Source evidence
20202020-04-30	Operating cash flow	-1391000	Operating Cash Flow: -1391000 Open source
20212021-04-30	Operating cash flow	-600000	Operating Cash Flow: -600000 Open source
20222022-04-30	Operating cash flow	-9921000	Operating Cash Flow: -9921000 Open source
20232023-04-30	Operating cash flow	-19833000	Operating Cash Flow: -19833000 Open source
20242024-04-30	Operating cash flow	-3184000	Operating Cash Flow: -3184000 Open source
20252025-04-30	Operating cash flow	-6410000	Operating Cash Flow: -6410000 Open source
20262026-04-30	Operating cash flow	-12463000	Operating Cash Flow: -12463000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

CAD -12.9M 2026

Values and sources

Free cash flow values and source evidence
Period	Series	Value(CAD)	Source evidence
20202020-04-30	Free cash flow	-1765000	Operating Cash Flow: -1391000 Open source Capital Expenditure: 374000 Open source
20212021-04-30	Free cash flow	-1975000	Operating Cash Flow: -600000 Open source Capital Expenditure: 1375000 Open source
20222022-04-30	Free cash flow	-10987000	Operating Cash Flow: -9921000 Open source Capital Expenditure: 1066000 Open source
20232023-04-30	Free cash flow	-21328000	Operating Cash Flow: -19833000 Open source Capital Expenditure: 1495000 Open source
20242024-04-30	Free cash flow	-4581000	Operating Cash Flow: -3184000 Open source Capital Expenditure: 1397000 Open source
20252025-04-30	Free cash flow	-7209000	Operating Cash Flow: -6410000 Open source Capital Expenditure: 799000 Open source
20262026-04-30	Free cash flow	-12861000	Operating Cash Flow: -12463000 Open source Capital Expenditure: 398000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

45% 2026

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-04-30	Liabilities / assets	44.7%	Total Liabilities: 12177000 Open source Total Assets: 27263000 Open source
20212021-04-30	Liabilities / assets	15%	Total Liabilities: 10035000 Open source Total Assets: 66959000 Open source
20222022-04-30	Liabilities / assets	19.5%	Total Liabilities: 18209000 Open source Total Assets: 93494000 Open source
20232023-04-30	Liabilities / assets	25.7%	Total Liabilities: 20010000 Open source Total Assets: 77813000 Open source
20242024-04-30	Liabilities / assets	40.5%	Total Liabilities: 24310000 Open source Total Assets: 59988000 Open source
20252025-04-30	Liabilities / assets	46.8%	Total Liabilities: 20815000 Open source Total Assets: 44441000 Open source
20262026-04-30	Liabilities / assets	45%	Total Liabilities: 9627000 Open source Total Assets: 21376000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.8× 2026

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-04-30	Current assets / current liabilities	0.97×	Current Assets: 7699000 Open source Current Liabilities: 7930000 Open source
20212021-04-30	Current assets / current liabilities	8.05×	Current Assets: 48858000 Open source Current Liabilities: 6072000 Open source
20222022-04-30	Current assets / current liabilities	4.05×	Current Assets: 37470000 Open source Current Liabilities: 9263000 Open source
20232023-04-30	Current assets / current liabilities	2.84×	Current Assets: 16792000 Open source Current Liabilities: 5920000 Open source
20242024-04-30	Current assets / current liabilities	1.41×	Current Assets: 11487000 Open source Current Liabilities: 8124000 Open source
20252025-04-30	Current assets / current liabilities	2.08×	Current Assets: 18754000 Open source Current Liabilities: 9012000 Open source
20262026-04-30	Current assets / current liabilities	2.8×	Current Assets: 16220000 Open source Current Liabilities: 5789000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2019-05-01 – 2020-04-30	Unavailable Not reported for this period.	−CAD 1.39 million Exact value Exact value: -1391000 CAD 2019-05-01 – 2020-04-30: -1391000 CAD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoPrecise Antibodies Ltd. · 2020-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Operating Cash Flow: -1391000 CAD Concept: fundies:OperatingCashFlow Period: 2019-05-01 to 2020-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925/explain?concept=fundies%3AOperatingCashFlow&period=2020-04-30&surface=latest&period_type=duration&start=2019-05-01&unit=CAD&dimensions= Input fundies:OperatingCashFlow: -1391000 CAD (2019-05-01 to 2020-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000156459021049295/ipa-20210430.xml#361825 Filing: 000156459021049295 The citation records this snapshot. The page link may show a newer release later.	CAD 374,000 Exact value Exact value: 374000 CAD 2019-05-01 – 2020-04-30: 374000 CAD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoPrecise Antibodies Ltd. · 2020-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Capital Expenditure: 374000 CAD Concept: fundies:CapitalExpenditure Period: 2019-05-01 to 2020-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925/explain?concept=fundies%3ACapitalExpenditure&period=2020-04-30&surface=latest&period_type=duration&start=2019-05-01&unit=CAD&dimensions= Input fundies:CapitalExpenditure: 374000 CAD (2019-05-01 to 2020-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000156459021049295/ipa-20210430.xml#362294 Filing: 000156459021049295 The citation records this snapshot. The page link may show a newer release later.	−CAD 1.77 million Calculation and evidence -1391000 − 374000 CAD Exact free cash flow: -1765000 CAD 2019-05-01 – 2020-04-30: -1391000 CAD · Inspect Operating Cash Flow · Source 2019-05-01 – 2020-04-30: 374000 CAD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoPrecise Antibodies Ltd. · 2020-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Free cash flow: -1765000 CAD Concept: free-cash-flow Period: 2019-05-01 to 2020-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1391000 CAD (2019-05-01 to 2020-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000156459021049295/ipa-20210430.xml#361825 Filing: 000156459021049295 Input fundies:CapitalExpenditure: 374000 CAD (2019-05-01 to 2020-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000156459021049295/ipa-20210430.xml#362294 Filing: 000156459021049295 The citation records this snapshot. The page link may show a newer release later.
2021 2020-05-01 – 2021-04-30	Unavailable Not reported for this period.	−CAD 600,000 Exact value Exact value: -600000 CAD 2020-05-01 – 2021-04-30: -600000 CAD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoPrecise Antibodies Ltd. · 2021-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Operating Cash Flow: -600000 CAD Concept: fundies:OperatingCashFlow Period: 2020-05-01 to 2021-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925/explain?concept=fundies%3AOperatingCashFlow&period=2021-04-30&surface=latest&period_type=duration&start=2020-05-01&unit=CAD&dimensions= Input fundies:OperatingCashFlow: -600000 CAD (2020-05-01 to 2021-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312522205824/d336384d40f_htm.xml#389542 Filing: 000119312522205824 The citation records this snapshot. The page link may show a newer release later.	CAD 1.38 million Exact value Exact value: 1375000 CAD 2020-05-01 – 2021-04-30: 1375000 CAD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoPrecise Antibodies Ltd. · 2021-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Capital Expenditure: 1375000 CAD Concept: fundies:CapitalExpenditure Period: 2020-05-01 to 2021-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925/explain?concept=fundies%3ACapitalExpenditure&period=2021-04-30&surface=latest&period_type=duration&start=2020-05-01&unit=CAD&dimensions= Input fundies:CapitalExpenditure: 1375000 CAD (2020-05-01 to 2021-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312522205824/d336384d40f_htm.xml#390000 Filing: 000119312522205824 The citation records this snapshot. The page link may show a newer release later.	−CAD 1.98 million Calculation and evidence -600000 − 1375000 CAD Exact free cash flow: -1975000 CAD 2020-05-01 – 2021-04-30: -600000 CAD · Inspect Operating Cash Flow · Source 2020-05-01 – 2021-04-30: 1375000 CAD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoPrecise Antibodies Ltd. · 2021-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Free cash flow: -1975000 CAD Concept: free-cash-flow Period: 2020-05-01 to 2021-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -600000 CAD (2020-05-01 to 2021-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312522205824/d336384d40f_htm.xml#389542 Filing: 000119312522205824 Input fundies:CapitalExpenditure: 1375000 CAD (2020-05-01 to 2021-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312522205824/d336384d40f_htm.xml#390000 Filing: 000119312522205824 The citation records this snapshot. The page link may show a newer release later.
2022 2021-05-01 – 2022-04-30	Unavailable Not reported for this period.	−CAD 9.92 million Exact value Exact value: -9921000 CAD 2021-05-01 – 2022-04-30: -9921000 CAD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoPrecise Antibodies Ltd. · 2022-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Operating Cash Flow: -9921000 CAD Concept: fundies:OperatingCashFlow Period: 2021-05-01 to 2022-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925/explain?concept=fundies%3AOperatingCashFlow&period=2022-04-30&surface=latest&period_type=duration&start=2021-05-01&unit=CAD&dimensions= Input fundies:OperatingCashFlow: -9921000 CAD (2021-05-01 to 2022-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000095017024087127/ipa-20240430.htm#2726963 Filing: 000095017024087127 The citation records this snapshot. The page link may show a newer release later.	CAD 1.07 million Exact value Exact value: 1066000 CAD 2021-05-01 – 2022-04-30: 1066000 CAD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoPrecise Antibodies Ltd. · 2022-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Capital Expenditure: 1066000 CAD Concept: fundies:CapitalExpenditure Period: 2021-05-01 to 2022-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925/explain?concept=fundies%3ACapitalExpenditure&period=2022-04-30&surface=latest&period_type=duration&start=2021-05-01&unit=CAD&dimensions= Input fundies:CapitalExpenditure: 1066000 CAD (2021-05-01 to 2022-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000095017024087127/ipa-20240430.htm#2734830 Filing: 000095017024087127 The citation records this snapshot. The page link may show a newer release later.	−CAD 10.99 million Calculation and evidence -9921000 − 1066000 CAD Exact free cash flow: -10987000 CAD 2021-05-01 – 2022-04-30: -9921000 CAD · Inspect Operating Cash Flow · Source 2021-05-01 – 2022-04-30: 1066000 CAD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoPrecise Antibodies Ltd. · 2022-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Free cash flow: -10987000 CAD Concept: free-cash-flow Period: 2021-05-01 to 2022-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9921000 CAD (2021-05-01 to 2022-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000095017024087127/ipa-20240430.htm#2726963 Filing: 000095017024087127 Input fundies:CapitalExpenditure: 1066000 CAD (2021-05-01 to 2022-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000095017024087127/ipa-20240430.htm#2734830 Filing: 000095017024087127 The citation records this snapshot. The page link may show a newer release later.
2023 2022-05-01 – 2023-04-30	Unavailable Not reported for this period.	−CAD 19.83 million Exact value Exact value: -19833000 CAD 2022-05-01 – 2023-04-30: -19833000 CAD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoPrecise Antibodies Ltd. · 2023-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Operating Cash Flow: -19833000 CAD Concept: fundies:OperatingCashFlow Period: 2022-05-01 to 2023-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925/explain?concept=fundies%3AOperatingCashFlow&period=2023-04-30&surface=latest&period_type=duration&start=2022-05-01&unit=CAD&dimensions= Input fundies:OperatingCashFlow: -19833000 CAD (2022-05-01 to 2023-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000095017025099392/ipa-20250430.htm#3157919 Filing: 000095017025099392 The citation records this snapshot. The page link may show a newer release later.	CAD 1.5 million Exact value Exact value: 1495000 CAD 2022-05-01 – 2023-04-30: 1495000 CAD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoPrecise Antibodies Ltd. · 2023-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Capital Expenditure: 1495000 CAD Concept: fundies:CapitalExpenditure Period: 2022-05-01 to 2023-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925/explain?concept=fundies%3ACapitalExpenditure&period=2023-04-30&surface=latest&period_type=duration&start=2022-05-01&unit=CAD&dimensions= Input fundies:CapitalExpenditure: 1495000 CAD (2022-05-01 to 2023-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000095017025099392/ipa-20250430.htm#3168428 Filing: 000095017025099392 The citation records this snapshot. The page link may show a newer release later.	−CAD 21.33 million Calculation and evidence -19833000 − 1495000 CAD Exact free cash flow: -21328000 CAD 2022-05-01 – 2023-04-30: -19833000 CAD · Inspect Operating Cash Flow · Source 2022-05-01 – 2023-04-30: 1495000 CAD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoPrecise Antibodies Ltd. · 2023-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Free cash flow: -21328000 CAD Concept: free-cash-flow Period: 2022-05-01 to 2023-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19833000 CAD (2022-05-01 to 2023-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000095017025099392/ipa-20250430.htm#3157919 Filing: 000095017025099392 Input fundies:CapitalExpenditure: 1495000 CAD (2022-05-01 to 2023-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000095017025099392/ipa-20250430.htm#3168428 Filing: 000095017025099392 The citation records this snapshot. The page link may show a newer release later.
2024 2023-05-01 – 2024-04-30	Unavailable Not reported for this period.	−CAD 3.18 million Exact value Exact value: -3184000 CAD 2023-05-01 – 2024-04-30: -3184000 CAD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoPrecise Antibodies Ltd. · 2024-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Operating Cash Flow: -3184000 CAD Concept: fundies:OperatingCashFlow Period: 2023-05-01 to 2024-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925/explain?concept=fundies%3AOperatingCashFlow&period=2024-04-30&surface=latest&period_type=duration&start=2023-05-01&unit=CAD&dimensions= Input fundies:OperatingCashFlow: -3184000 CAD (2023-05-01 to 2024-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3099239 Filing: 000119312526312694 The citation records this snapshot. The page link may show a newer release later.	CAD 1.4 million Exact value Exact value: 1397000 CAD 2023-05-01 – 2024-04-30: 1397000 CAD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoPrecise Antibodies Ltd. · 2024-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Capital Expenditure: 1397000 CAD Concept: fundies:CapitalExpenditure Period: 2023-05-01 to 2024-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925/explain?concept=fundies%3ACapitalExpenditure&period=2024-04-30&surface=latest&period_type=duration&start=2023-05-01&unit=CAD&dimensions= Input fundies:CapitalExpenditure: 1397000 CAD (2023-05-01 to 2024-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3109985 Filing: 000119312526312694 The citation records this snapshot. The page link may show a newer release later.	−CAD 4.58 million Calculation and evidence -3184000 − 1397000 CAD Exact free cash flow: -4581000 CAD 2023-05-01 – 2024-04-30: -3184000 CAD · Inspect Operating Cash Flow · Source 2023-05-01 – 2024-04-30: 1397000 CAD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoPrecise Antibodies Ltd. · 2024-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Free cash flow: -4581000 CAD Concept: free-cash-flow Period: 2023-05-01 to 2024-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3184000 CAD (2023-05-01 to 2024-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3099239 Filing: 000119312526312694 Input fundies:CapitalExpenditure: 1397000 CAD (2023-05-01 to 2024-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3109985 Filing: 000119312526312694 The citation records this snapshot. The page link may show a newer release later.
2025 2024-05-01 – 2025-04-30	Unavailable Not reported for this period.	−CAD 6.41 million Exact value Exact value: -6410000 CAD 2024-05-01 – 2025-04-30: -6410000 CAD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoPrecise Antibodies Ltd. · 2025-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Operating Cash Flow: -6410000 CAD Concept: fundies:OperatingCashFlow Period: 2024-05-01 to 2025-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925/explain?concept=fundies%3AOperatingCashFlow&period=2025-04-30&surface=latest&period_type=duration&start=2024-05-01&unit=CAD&dimensions= Input fundies:OperatingCashFlow: -6410000 CAD (2024-05-01 to 2025-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3097355 Filing: 000119312526312694 The citation records this snapshot. The page link may show a newer release later.	CAD 799,000 Exact value Exact value: 799000 CAD 2024-05-01 – 2025-04-30: 799000 CAD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoPrecise Antibodies Ltd. · 2025-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Capital Expenditure: 799000 CAD Concept: fundies:CapitalExpenditure Period: 2024-05-01 to 2025-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925/explain?concept=fundies%3ACapitalExpenditure&period=2025-04-30&surface=latest&period_type=duration&start=2024-05-01&unit=CAD&dimensions= Input fundies:CapitalExpenditure: 799000 CAD (2024-05-01 to 2025-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3108220 Filing: 000119312526312694 The citation records this snapshot. The page link may show a newer release later.	−CAD 7.21 million Calculation and evidence -6410000 − 799000 CAD Exact free cash flow: -7209000 CAD 2024-05-01 – 2025-04-30: -6410000 CAD · Inspect Operating Cash Flow · Source 2024-05-01 – 2025-04-30: 799000 CAD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoPrecise Antibodies Ltd. · 2025-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Free cash flow: -7209000 CAD Concept: free-cash-flow Period: 2024-05-01 to 2025-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6410000 CAD (2024-05-01 to 2025-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3097355 Filing: 000119312526312694 Input fundies:CapitalExpenditure: 799000 CAD (2024-05-01 to 2025-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3108220 Filing: 000119312526312694 The citation records this snapshot. The page link may show a newer release later.
2026 2025-05-01 – 2026-04-30	Unavailable Not reported for this period.	−CAD 12.46 million Exact value Exact value: -12463000 CAD 2025-05-01 – 2026-04-30: -12463000 CAD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoPrecise Antibodies Ltd. · 2026-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Operating Cash Flow: -12463000 CAD Concept: fundies:OperatingCashFlow Period: 2025-05-01 to 2026-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925/explain?concept=fundies%3AOperatingCashFlow&period=2026-04-30&surface=latest&period_type=duration&start=2025-05-01&unit=CAD&dimensions= Input fundies:OperatingCashFlow: -12463000 CAD (2025-05-01 to 2026-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3095470 Filing: 000119312526312694 The citation records this snapshot. The page link may show a newer release later.	CAD 398,000 Exact value Exact value: 398000 CAD 2025-05-01 – 2026-04-30: 398000 CAD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoPrecise Antibodies Ltd. · 2026-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Capital Expenditure: 398000 CAD Concept: fundies:CapitalExpenditure Period: 2025-05-01 to 2026-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925/explain?concept=fundies%3ACapitalExpenditure&period=2026-04-30&surface=latest&period_type=duration&start=2025-05-01&unit=CAD&dimensions= Input fundies:CapitalExpenditure: 398000 CAD (2025-05-01 to 2026-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3106453 Filing: 000119312526312694 The citation records this snapshot. The page link may show a newer release later.	−CAD 12.86 million Calculation and evidence -12463000 − 398000 CAD Exact free cash flow: -12861000 CAD 2025-05-01 – 2026-04-30: -12463000 CAD · Inspect Operating Cash Flow · Source 2025-05-01 – 2026-04-30: 398000 CAD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoPrecise Antibodies Ltd. · 2026-04-30 ImmunoPrecise Antibodies Ltd. (edgar:1715925) Free cash flow: -12861000 CAD Concept: free-cash-flow Period: 2025-05-01 to 2026-04-30 Values: Latest reported Published: 2026-11-02T18:07:10Z Snapshot: 09057c5f3141e058b67b32c48c3f01986a1597c3f75f174f9dbf304be3ded0a4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1715925?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12463000 CAD (2025-05-01 to 2026-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3095470 Filing: 000119312526312694 Input fundies:CapitalExpenditure: 398000 CAD (2025-05-01 to 2026-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/hyft-20260430.htm#3106453 Filing: 000119312526312694 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

234 filings · 940 latest values · 940 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001715925, 1715925, HYFT, IPA, edgar:1715925

Also known as ImmunoPrecise Antibodies Ltd. , MindWalk Holdings Corp., MindWalk Holdings Corp. , IMMUNOPRECISE ANTIBODIES LTD., ImmunoPrecise Antibodies Ltd., MindWalk Holdings Corp.

ImmunoPrecise Antibodies Ltd.

Latest quarter

Revenue

Free cash flow margin

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Operating cash flow

Capital expenditure

Where revenue goes

2026 2025-05-01 – 2026-04-30

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation